Practical guide · Learn
How to Read a Peptide COA (Purity)
Knowing how to read a peptide coa means checking two different claims: high-performance liquid chromatography (HPLC) estimates purity, while mass spectrometry checks molecular identity. Then match the sample, batch, dates, and laboratory to the product. A polished peptide certificate of analysis proves a tested sample—not necessarily the vial in your hand.
What does a peptide COA actually prove?
A peptide COA records what a laboratory found in the sample it received under the methods listed on the report. A credible result can support identity and purity for that sample. The peptide COA does not, by itself, prove who collected the sample, whether the sample represents an entire batch, or whether your vial came from that batch.
That gap is the part glossy PDFs tend to misplace. Traceability is the bridge: the report needs a sample or lot identifier matching the product, plus dates and enough laboratory information to verify the report. A vendor-selected sample carries less assurance than a sealed retail vial submitted independently.
FDA rules for pharmaceutical manufacturing illustrate the principle: supplier results must be shown reliable, and identity testing still matters. “Third-party tested” alone establishes neither.
How do you read peptide HPLC purity?
Peptide HPLC purity is usually the target peak’s integrated area divided by the total integrated area of detected peaks, reported as a percentage. Read the chromatogram, not just the large number. The report should identify the method, detector, column or method reference, retention time, individual peaks, and how the stated percentage was calculated.
HPLC separates compounds through a column. The chromatogram plots detector response against retention time; each resolved peak represents material detected then. A dominant target peak supports high relative purity under that method.
| COA field | What it tells you | What it does not tell you |
|---|---|---|
| Main-peak area % | Relative chromatographic purity | Exact peptide mass in the vial |
| Retention time | When the peak left that column under that method | Identity by itself |
| Minor peaks | Detected, separated impurities | Every possible impurity |
| Method details | Whether the result can be interpreted or repeated | That the submitted sample matches your vial |
Peptide HPLC purity is not peptide content. Water, counterions, salts, and detector response can make net peptide content differ from the headline percentage; closely eluting compounds can also share a peak. NIH-hosted recommendations therefore pair an HPLC-UV chromatogram with mass-spectrometry data and treat net peptide content separately.
What does mass spectrometry confirm on a peptide COA?
Mass spectrometry supports identity by comparing the peptide’s expected molecular mass with the observed mass-to-charge signals. A useful spectrum names the expected and observed values and explains the ion or charge state. A matching molecular mass is strong identity evidence, but a bare “PASS” or unlabeled spectrum gives the buyer little to check.
Peptides can appear at several charge states, and adducts can shift displayed signals. The report should explain them. Tandem mass spectrometry, written MS/MS, adds sequence-specific evidence by comparing fragments.
Mass spectrometry does not replace HPLC; the correct peptide can coexist with impurities. FDA’s synthetic-peptide guidance discusses high-resolution liquid chromatography–mass spectrometry for characterizing peptide-related impurities. Identity and purity remain separate jobs.
Which details should a real peptide certificate of analysis show?
A useful peptide certificate of analysis connects a named sample to a specific result and shows enough raw output to audit the conclusion. At minimum, look for the peptide name, batch or lot, sample identifier, test and report dates, laboratory identity, analytical method, acceptance criteria, actual results, and an authorized review or signature.
Use this order when learning how to read peptide test results:
- Match the batch. The report number should match the vial or documented batch.
- Check the timeline. Receipt, analysis, and report dates should make sense.
- Identify the laboratory. Verify it through the laboratory’s own contact information.
- Read the methods. Look for HPLC purity and mass-spectrometry identity data.
- Inspect the outputs. Raw pages and summary should share sample identifiers.
- Separate each claim. Identity, purity, content, sterility, and endotoxin require different tests.
The broader guide to spotting quality peptides covers packaging, testing scope, and seller claims. This page stays in the narrower lane: what the analytical pages can and cannot support.
What are the warning signs of a fake or weak peptide COA?
A weak peptide COA hides the connection between sample and result. Red flags include no batch number, reusable results across lots, cropped chromatograms, missing axes, a purity percentage without peak integration, a mass spectrum without expected and observed mass, inconsistent sample IDs, or a laboratory that cannot confirm the report.
“Third-party tested” is not a method. A logo, signature, or QR code can improve presentation without improving evidence. Verify through the laboratory’s own contact channel using the report or sample number. Appearance cannot authenticate an editable PDF.
Watch for category errors. A mass match is not 99% purity. A 99% HPLC result is not proof of 10 mg net peptide content. Identity testing is not sterility testing.
Can a COA prove that a peptide vial is safe?
A standard HPLC-plus-mass-spec COA cannot prove that a peptide vial is safe, sterile, correctly filled, or suitable for human use. Those claims require different sampling and tests. Even a technically sound report remains evidence about the submitted sample, so chain of custody and batch matching determine how far the conclusion travels.
Sterility, bacterial endotoxins, residual solvents, water, net peptide content, and fill quantity are separate attributes. No missing test should be smuggled into “purity.” FDA flags peptide-related impurities and active-ingredient characterization as concerns for several compounded peptides, including BPC-157.
The label also matters. “Research use only” has a specific practical meaning: the material is being sold for laboratory research, not as an FDA-reviewed medicine. A COA can describe research material; the PDF does not convert that material into an approved drug.
How should you compare two peptide COAs?
Compare peptide COAs only after confirming that they test the same peptide form with reasonably comparable methods. Start with batch traceability, then identity evidence, chromatographic method and raw trace, reported purity, and separate content or contamination tests. A larger purity number is not automatically better when one report shows its work and the other does not.
The cleanest comparison asks four questions: Can the laboratory confirm the report? Does the tested batch match the product? Do HPLC and mass spectrometry support separate purity and identity claims? Are sterility or content claims backed by their own results? That framework works across the wider peptide reference without pretending one PDF can answer everything.